Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171894 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
A Phase 2 study of Port-Wine Stain and Port-wine Birthmarks, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 5
- Study locations
NCT05171894: Recruiting Phase 2 study of Port-Wine Stain and Port-wine Birthmarks, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co..
NCT05171894 is a Phase 2 study of Port-Wine Stain and Port-wine Birthmarks that is actively recruiting participants, run by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05171894, a Phase 2 study of Port-Wine Stain and Port-wine Birthmarks, is actively recruiting participants, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
Primary Outcome
To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB) in the extremities, trunk, caudal cervical, and/or retroauricular area
Conditions Studied
Interventions
- DRUG Hemopfin+Green Light
- DEVICE Vehicle+Green Light
Study Locations (5)
California
- UCI Health Beckman Laser Institute & Medical Clinic - Irvine
- Dermatology Cosmetic Associates of La Jolla, Inc. d/b/a West Dermatology Research Center - San Diego
Florida
- Miami Dermatology and Laser Institute - Miami
Maryland
- Maryland Dermatology, Laser, Skin & Vein Institute - Hunt Valley
Pennsylvania
- St. Luke's University Health Network - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-09-21 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT05171894 shows while recruiting
NCT05171894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 3 conditions, with Port-Wine Stain appearing as the primary indexed condition, and to 2 interventions - of which Hemopfin+Green Light is the first listed.
NCT05171894 lists 5 locations in 4 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT05171894 about?
NCT05171894 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT". This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 75 years old with PWB will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
What is the current status of trial NCT05171894?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-09-21. Estimated completion is 2027-04.
What conditions does trial NCT05171894 study?
This clinical trial studies the following conditions: Port-Wine Stain, Port-wine Birthmarks, Nevus Flammeus.
What interventions are being tested in trial NCT05171894?
The interventions under investigation include: Hemopfin+Green Light (DRUG), Vehicle+Green Light (DEVICE).
Who is sponsoring clinical trial NCT05171894?
This trial is sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05171894 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Port-Wine Stain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05171894's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI